These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 10492628)

  • 1. A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer.
    Tierney GM; Griffin NR; Stuart RC; Kasem H; Lynch KP; Lury JT; Brown PD; Millar AW; Steele RJ; Parsons SL
    Eur J Cancer; 1999 Apr; 35(4):563-8. PubMed ID: 10492628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen.
    Primrose JN; Bleiberg H; Daniel F; Van Belle S; Mansi JL; Seymour M; Johnson PW; Neoptolemos JP; Baillet M; Barker K; Berrington A; Brown PD; Millar AW; Lynch KP
    Br J Cancer; 1999 Feb; 79(3-4):509-14. PubMed ID: 10027321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer.
    Wojtowicz-Praga S; Torri J; Johnson M; Steen V; Marshall J; Ness E; Dickson R; Sale M; Rasmussen HS; Chiodo TA; Hawkins MJ
    J Clin Oncol; 1998 Jun; 16(6):2150-6. PubMed ID: 9626215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial.
    Bramhall SR; Hallissey MT; Whiting J; Scholefield J; Tierney G; Stuart RC; Hawkins RE; McCulloch P; Maughan T; Brown PD; Baillet M; Fielding JW
    Br J Cancer; 2002 Jun; 86(12):1864-70. PubMed ID: 12085177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
    Goffin JR; Anderson IC; Supko JG; Eder JP; Shapiro GI; Lynch TJ; Shipp M; Johnson BE; Skarin AT
    Clin Cancer Res; 2005 May; 11(9):3417-24. PubMed ID: 15867243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Marimastat in patients with advanced pancreatic cancer: a dose-finding study.
    Rosemurgy A; Harris J; Langleben A; Casper E; Goode S; Rasmussen H
    Am J Clin Oncol; 1999 Jun; 22(3):247-52. PubMed ID: 10362330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers.
    Millar AW; Brown PD; Moore J; Galloway WA; Cornish AG; Lenehan TJ; Lynch KP
    Br J Clin Pharmacol; 1998 Jan; 45(1):21-6. PubMed ID: 9489589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial.
    Rosenbaum E; Zahurak M; Sinibaldi V; Carducci MA; Pili R; Laufer M; DeWeese TL; Eisenberger MA
    Clin Cancer Res; 2005 Jun; 11(12):4437-43. PubMed ID: 15958628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II trial of marimastat in advanced pancreatic cancer.
    Evans JD; Stark A; Johnson CD; Daniel F; Carmichael J; Buckels J; Imrie CW; Brown P; Neoptolemos JP
    Br J Cancer; 2001 Dec; 85(12):1865-70. PubMed ID: 11747327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer.
    Shepherd FA; Giaccone G; Seymour L; Debruyne C; Bezjak A; Hirsh V; Smylie M; Rubin S; Martins H; Lamont A; Krzakowski M; Sadura A; Zee B
    J Clin Oncol; 2002 Nov; 20(22):4434-9. PubMed ID: 12431965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer.
    Miller KD; Gradishar W; Schuchter L; Sparano JA; Cobleigh M; Robert N; Rasmussen H; Sledge GW
    Ann Oncol; 2002 Aug; 13(8):1220-4. PubMed ID: 12181245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dupuytren's disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor.
    Hutchinson JW; Tierney GM; Parsons SL; Davis TR
    J Bone Joint Surg Br; 1998 Sep; 80(5):907-8. PubMed ID: 9768907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Marimastat (BB2516): current status of development.
    Steward WP
    Cancer Chemother Pharmacol; 1999; 43 Suppl():S56-60. PubMed ID: 10357560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies.
    Nemunaitis J; Poole C; Primrose J; Rosemurgy A; Malfetano J; Brown P; Berrington A; Cornish A; Lynch K; Rasmussen H; Kerr D; Cox D; Millar A
    Clin Cancer Res; 1998 May; 4(5):1101-9. PubMed ID: 9607566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I and pharmacological study of the matrix metalloproteinase inhibitor BB-3644 in patients with solid tumours.
    Wall L; Talbot DC; Bradbury P; Jodrell DI
    Br J Cancer; 2004 Feb; 90(4):800-4. PubMed ID: 14970856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastroesophageal cancer, palmar fasciitis and a matrix metalloproteinase inhibitor.
    Virik K; Lynch KP; Harper P
    Intern Med J; 2002; 32(1-2):50-1. PubMed ID: 11783676
    [No Abstract]   [Full Text] [Related]  

  • 17. Inhibition of tumour growth by marimastat in a human xenograft model of gastric cancer: relationship with levels of circulating CEA.
    Watson SA; Morris TM; Collins HM; Bawden LJ; Hawkins K; Bone EA
    Br J Cancer; 1999 Sep; 81(1):19-23. PubMed ID: 10487607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised double blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor, Marimastat in patients with inoperable colorectal hepatic metastases: significant survival advantage in patients with musculoskeletal side-effects.
    King J; Zhao J; Clingan P; Morris D
    Anticancer Res; 2003; 23(1B):639-45. PubMed ID: 12680160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Marimastat: the clinical development of a matrix metalloproteinase inhibitor.
    Steward WP; Thomas AL
    Expert Opin Investig Drugs; 2000 Dec; 9(12):2913-22. PubMed ID: 11093361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dose-finding and pharmacokinetic study of the matrix metalloproteinase inhibitor MMI270 (previously termed CGS27023A) with 5-FU and folinic acid.
    Eatock M; Cassidy J; Johnson J; Morrison R; Devlin M; Blackey R; Owen S; Choi L; Twelves C
    Cancer Chemother Pharmacol; 2005 Jan; 55(1):39-46. PubMed ID: 15368080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.